Blog

NIAGARA study vs. dose-dense MVAC: Chandler Park’s discussion with Petros Grivas

Collage photo of Chandler Park and Petros Grivas

Oct 21, 2024, 16:58

NIAGARA study vs. dose-dense MVAC: Chandler Park’s discussion with Petros Grivas

Chandler Park, Advisory Dean and Clinical Professor at University of Louisville School of Medicine, shared a post on LinkedIn:

“Based on NIAGARA study released in 9/2024. Perioperative Cisplatin Gemcitabine and Durvalumab is the new Standard of care for patients with highest rate of cure.

NEJM

Full video

However, what about use of dose-dense MVAC that many of us use for higher pathological complete response.

My great friend Petros Grivas MD and I discuss how this impacts the clinical practice of cancer physicians to best treat our bladder and urothelial cancer.”

Proceed to the video attached to the post.

More posts featuring Chandler Park and Petros Grivas.

Chandler Park, MD, FACP is an haematologist oncologist, medical journalist, and clinical researcher. He is the Advisory Dean and Clinical Professor at University of Louisville School of Medicine. He is the Kentucky Physician Representative of the ASCO State Executive Council. He is also the Medical Oncology Board Examiner at American Board of Internal Medicine.

Petros Grivas, a board-certified medical oncologist, serves as Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance. He’s an Associate Professor at the Dept. of Medicine and Associate Member at Fred Hutchinson Cancer Research Center since January 2018. With extensive training and experience, he’s led clinical trials, contributing to FDA approvals for bladder/urothelial cancer treatments.